8-K
filed October 22, 2024, 7:59 PM ET
ticker IKT
CIK 0001750149
other material
confidence high
sentiment positive
materiality 0.90
Inhibikase closes $110M private placement, up to $275M total, advances IkT-001Pro in PAH
Inhibikase Therapeutics, Inc.
- Gross proceeds ~$110M from private placement; potential aggregate up to ~$275M from warrant exercises.
- Proceeds to fund Phase 2b '702' trial of IkT-001Pro in PAH and for general corporate purposes.
- Appointed four new directors: Roberto Bellini (Independent Chair), Amit Munshi, David Canner, Arvind Kush.
- Resignations of Dr. Paul Grint and Gisele Dion, not due to disagreements; fully vested options paid through Dec 31, 2024.
- IkT-001Pro is oral, potentially disease-modifying imatinib prodrug aiming to improve safety/tolerability in PAH.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Roberto Bellini was appointed as Class I director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class I director
Exact text from the filing
the Board appointed Roberto Bellini to serve as a Class I director of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Roberto Bellini was elected as Independent Chairperson of the Board at Inhibikase Therapeutics, Inc..
- Action
- elected
- Role
- Independent Chairperson of the Board
Exact text from the filing
The Board has elected Mr. Bellini as independent Chairperson of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Arvind Kush was appointed as Class III director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class III director
Exact text from the filing
Arvind Kush to serve as a Class III director of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul Grint resigned as director at Inhibikase Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Canner was appointed as Class II director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class II director
Exact text from the filing
Amit Munshi and David Canner to serve as Class II directors of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Gisele Dion resigned as director at Inhibikase Therapeutics, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Amit Munshi was appointed as Class II director at Inhibikase Therapeutics, Inc..
- Action
- appointed
- Role
- Class II director
Exact text from the filing
Amit Munshi and David Canner to serve as Class II directors of the Board
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.